Novocure Reports First Quarter 2018 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
NovoCure Ltd. (NVCR) PT Raised to $31 at Deutsche Bank
April 27, 2018 7:46 AM EDTDeutsche Bank raised its price target on NovoCure Ltd. (NASDAQ: NVCR) to $31.00 (from $29.00) while maintaining a Buy rating.
Analyst Gregg Gilbert commented, "NVCR reported strong patient uptake in GBM globally, with US contributing a majority of the increase in patient numbers... More
